Russian Chemical Bulletin

, Volume 49, Issue 9, pp 1613–1619 | Cite as

Synthesis, structure, and biological activity of mixed-ligand platinum(II) complexes with aminonitroxides

  • V. D. Sen
  • N. A. Rukina
  • V. V. Tkachev
  • A. V. Pis'menskii
  • L. M. Volkova
  • S. A. Goncharova
  • T. A. Raevskaya
  • A. G. Tikhomirov
  • L. B. Gorbacheva
  • N. P. Konovalova
Organometallic Chemistry

Abstract

Mixed-ligand platinum complexescis-PtII(R6NH2)(NH3)X2 andcis-PtII(R5NH2)(NH3)X2 (R6 is 2,2,6,6-tetramethyl-4-piperidyl-1-oxyl and R5 is 2,2,5,5-tetramethyl-3-pyrrolidinyl-1-oxyl) were synthesized by either the reaction of aminonitroxides RNH2 with Na[PtII(NH3)Cl2I] generatedin situ (for X2=ClI) or by replacement of the iodo-chloro ligands incis-Pt11(RNH2)(NH3)ClI by dichloro and oxalato ligands. The complexes obtained were characterized by elemental analysis and by IR, UV, and ESR spectra. Forcis-Pt11(R5NH2)(NH3)Cl2, crystal and molecular structures were determined by X-ray diffraction analysis. Cisplatin accelerates autooxidation of methyl linoleate and the platinum nitroxide complexes synthesized exhibit antioxidant properties. The rate of isolated DNA binding with the new complexes is almost as high as that for cisplatin.cis-Pt11(R6NH2)(NH3)Cl2 exhibits the highest antitumor activity. The high antitumor activity of platinum nitroxide complexes shows that the possible “radical component” is not a crucial factor in the cytotoxic action of cisplatin.

Key words

platinum(II) complexes nitroxides structure antioxidants antitumor activity cytotoxicity cisplatin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. J. Bloemink and J. Reedijk, inMetal Ions in Biological Systems, Eds. H. Sigel and A. Sigel: M. Dekker, New York, 1996,32, p. 641.Google Scholar
  2. 2.
    D. L. Evans and C. Dive,Cancer Res., 1993,53, 2133.Google Scholar
  3. 3.
    A. Miyajima, J. Nakashima, K. Yoshioka, M. Tachibana, H. Tazaki, and M. Murai,Br. J. Cancer, 1997,76, 210.Google Scholar
  4. 4.
    K. Sugihara, S. Nakano, and M. Gemba,Jpn. J. Pharmacol., 1987,44, 71.Google Scholar
  5. 5.
    R. Ravi, S. M. Somani, and L. P. Rybak,Pharmacol. Toxicol., 1995,76, 386.CrossRefGoogle Scholar
  6. 6.
    Y. Torri, M. Mutoh, H. Saito, and N. Matsuki,Eur. J. Pharmacol., 1993,248, 131.Google Scholar
  7. 7.
    V. D. Sen', V. A. Golubev, I. V. Kulyk, and E. G. Rozantsev,Izv. Akad. Nauk SSSR, Ser. Khim. 1976, 1745 [Bull. Acad. Sci. USSR, Div. Chem. Sci., 1976,25 (Engl. Transl.)].Google Scholar
  8. 8.
    S. I. Skuratova, Yu. N. Kozlov, N. V. Zakatova, and V. A. Sharpatyl,Zh. Fiz. Khim., 1971,45, 1821 [J. Phys. Chem. USSR, 1971,45 (Engl. Transl.)].Google Scholar
  9. 9.
    D. B. Korman, A. M. Garin, M. L. Gershanovich, V. M. Moiseenko, V. A. Snimchicov, S. A. Zharcov, P. Seminara, L. Gargano, and F. Franchi,J. Exp. Clin. Cancer Res., 1995,14, 65.Google Scholar
  10. 10.
    V. D. Sen', A. V. Kulikov, A. V. Shugalii, and N. P. Konovalova,Izv. Akad. Nauk, Ser. Khim., 1998, 1640 [Russ. Chem. Bull., 1998,47, 1598 (Engl. Transl.)].Google Scholar
  11. 11.
    E. G. Rozantsev,Svobodnye iminoksil'nye radikaly [Iminoxyl Free Radicals], Khimiya, Moscow, 1970, p. 186, p. 200 (in Russian).Google Scholar
  12. 12.
    C. M. Giandomenico, M. J. Abrams, B. A. Murrer, J. F. Vollano, M. I. Rheinheimer, S. B. Wyer, G. E. Bossard, and J. D. Higgins,Inorg. Chem., 1995,34, 1015.CrossRefGoogle Scholar
  13. 13.
    S. U. Dunham and S. J. Lippard,J. Am. Chem. Soc., 1995,117, 10702.CrossRefGoogle Scholar
  14. 14.
    USSR Pat. 582481;Byull. Izobret. [Invent Bull.], 1977, 44 (in Russian).Google Scholar
  15. 15.
    T. R. Brent,Cancer Res., 1984,44, 1887.Google Scholar
  16. 16.
    T. G. Talman, W. Bruning, J. Reedijk, A. L. Spek, and N. Veldman,Inorg. Chem., 1997,36, 854.CrossRefGoogle Scholar
  17. 17.
    H. Ito, J. Fujita, and K. Saito,Bull. Chem. Soc. Jpn., 1967,40, 2584.CrossRefGoogle Scholar
  18. 18.
    T. V. Hambley,Coord. Chem. Rev., 1997,166, 181.CrossRefGoogle Scholar
  19. 19.
    A. V. Shugalii, A. V. Kulikov, M. V. Lichina, V. A. Golubev, and V. D. Sen',J. Inorg. Biochem., 1998,69, 67.CrossRefGoogle Scholar
  20. 20.
    N. P. Konovalova, R. F. Diatchkovskaya, L. H. Ganieva, L. M. Volkova, and A. B. Shapiro,Neoplasma, 1991,38, 275.Google Scholar
  21. 21.
    G. Sosnovsky and S. W. Li,Drug Future, 1985,36, 1379.Google Scholar
  22. 22.
    N. P. Konovalova, R. F. Diatchkovskaya, L. M. Volkova, and V. N. Varfolomeev,Anti-Cancer Drugs, 1991,2, 591.Google Scholar
  23. 23.
    K. Takechi, H. Tamura, K. Yamaoka, and H. Sakurai,Free Rad. Res., 1997,26, 483.CrossRefGoogle Scholar
  24. 24.
    H. Masuda, T. Tanaka, and S. Matsushima,Anticancer Res., 1998,18, 1473.Google Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 2000

Authors and Affiliations

  • V. D. Sen
    • 1
  • N. A. Rukina
    • 1
  • V. V. Tkachev
    • 1
  • A. V. Pis'menskii
    • 1
  • L. M. Volkova
    • 1
  • S. A. Goncharova
    • 1
  • T. A. Raevskaya
    • 1
  • A. G. Tikhomirov
    • 2
  • L. B. Gorbacheva
    • 2
  • N. P. Konovalova
    • 1
  1. 1.Institute of Problems of Chemical PhysicsRussian Academy of SciencesChernogolovkaRussian Federation
  2. 2.N. M. Emanuel' Institute of Biochemical PhysicsRussian Academy of SciencesMoscowRussian Federation

Personalised recommendations